Stockreport

pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study

PSIVIDA  (PSDV) 
Last psivida earnings: 2/7 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.psivida.com
PDF Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 [Read more]